BioRestorative Therapies Inc (BRTX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
BioRestorative Therapies Inc stock (BRTX) is currently trading at $0.29. BioRestorative Therapies Inc PS ratio (Price-to-Sales) is 15.77. Analyst consensus price target for BRTX is $9.50. WallStSmart rates BRTX as Sell.
- BRTX PE ratio analysis and historical PE chart
- BRTX PS ratio (Price-to-Sales) history and trend
- BRTX intrinsic value — DCF, Graham Number, EPV models
- BRTX stock price prediction 2025 2026 2027 2028 2029 2030
- BRTX fair value vs current price
- BRTX insider transactions and insider buying
- Is BRTX undervalued or overvalued?
- BioRestorative Therapies Inc financial analysis — revenue, earnings, cash flow
- BRTX Piotroski F-Score and Altman Z-Score
- BRTX analyst price target and Smart Rating
BioRestorative Therapies Inc
📊 No data available
Try selecting a different time range
Smart Analysis
BioRestorative Therapies Inc (BRTX) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
BioRestorative Therapies Inc (BRTX) Key Strengths (0)
Supporting Valuation Data
BioRestorative Therapies Inc (BRTX) Areas to Watch (7)
Company is destroying shareholder value
Losing money on operations
Revenue declining -94.90%, a shrinking business
Very expensive at 15.8x annual revenue
Very low institutional interest at 5.38%
Micro-cap company with very limited liquidity and high volatility
Fairly priced relative to book value
Supporting Valuation Data
BioRestorative Therapies Inc (BRTX) Detailed Analysis Report
Overall Assessment
This company scores 14/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 0 register as strengths (avg 0/10) while 7 fall into concern territory (avg 1.9/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
Limited fundamental strengths were identified. The bull case requires improvement in core metrics.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including Price/Sales (15.77), Price/Book (2.65) suggest expensive pricing. Growth concerns include Revenue Growth at -94.90%, which may limit upside. Profitability pressure is visible in Return on Equity at -207.70%, Operating Margin at -31432.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -207.70% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -94.90% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
BRTX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
BRTX's Price-to-Sales ratio of 15.77x sits near its historical average of 14.41x (57th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 8% below its historical high of 17.07x set in Mar 2026, and 31% above its historical low of 12x in Mar 2026. Over the past 12 months, the PS ratio has expanded from ~14.1x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for BioRestorative Therapies Inc (BRTX) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
BioRestorative Therapies Inc operates as a stable business with moderate growth and solid fundamentals. Revenue reached 383,400 with 95% decline year-over-year.
Key Findings
Spending 677% of revenue (3M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 95% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -3M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact BioRestorative Therapies Inc.
Bottom Line
BioRestorative Therapies Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About BioRestorative Therapies Inc(BRTX)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols that primarily involve adult stem cells. The company is headquartered in Melville, New York.